Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.
OBJECTIVE
To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab.


METHODS
The medical records of a patient with peripheral exudative chorioretinopathy were reviewed.


RESULTS
Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course.


CONCLUSIONS
Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Andrew J
AJ
Barkmeier
Huseyin
H
Kadikoy
Eric R
ER
Holz
Petros E
PE
Carvounis
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012166:Retinal Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab